Efficacy and tolerability of oxaprozin in the elderly

摘要: Retrospective data from controlled clinical trials with Oxaprozin, an investigational nonsteroidal antiinflammatory drug (NSAID), were stratified by patient age to ascertain whether the is as safe and effective in patients over 60 years old it younger patients. Data for 1.423 rheumatoid arthritis (RA) osteoarthritis (OA) studied; 1,012 of these received Oxaprozin (600 1,800 mg daily), 232 aspirin (2,600 3,900 179 ibuprofen (1,200 2,400 daily). The three drugs equally treating RA OA, efficacy measures indicated similar improvement both groups. Elderly who aspirin, or more likely have gastrointestinal hematologic adverse effects than their counterparts, older therapy also renal effects. incidence hepatic side was very low comparable all drugs, Thus, no other NSAIDs increase risk gastrointestinal, hematologic, toxicity among elderly forms varies depending on underlying disease. Such factors concomitant disease, organ dysfunction, medication may contribute increased NSAID observed